Artykuły w czasopismach na temat „Oncohistone H3.3 K27M”
Utwórz poprawne odniesienie w stylach APA, MLA, Chicago, Harvard i wielu innych
Sprawdź 50 najlepszych artykułów w czasopismach naukowych na temat „Oncohistone H3.3 K27M”.
Przycisk „Dodaj do bibliografii” jest dostępny obok każdej pracy w bibliografii. Użyj go – a my automatycznie utworzymy odniesienie bibliograficzne do wybranej pracy w stylu cytowania, którego potrzebujesz: APA, MLA, Harvard, Chicago, Vancouver itp.
Możesz również pobrać pełny tekst publikacji naukowej w formacie „.pdf” i przeczytać adnotację do pracy online, jeśli odpowiednie parametry są dostępne w metadanych.
Przeglądaj artykuły w czasopismach z różnych dziedzin i twórz odpowiednie bibliografie.
Liu, Ilon, Jiang Li, Daeun Jeong, Olivia A. Hack, McKenzie Shaw, Bernhard Englinger, Byron Avihai i in. "EPCO-06. AGE- AND REGION-SPECIFIC MULTI-OMIC CHARACTERIZATION OF H3-K27M MUTANT DIFFUSE MIDLINE GLIOMA". Neuro-Oncology 23, Supplement_6 (2.11.2021): vi2. http://dx.doi.org/10.1093/neuonc/noab196.005.
Pełny tekst źródłaLiu, I., L. Jiang, E. Samuelsson, S. Marco Salas, O. Hack, D. Jeong, M. Shaw i in. "JS04.6.A The landscape of tumor cell states and spatial organization in H3-K27M mutant diffuse midline glioma across age and location". Neuro-Oncology 24, Supplement_2 (1.09.2022): ii7. http://dx.doi.org/10.1093/neuonc/noac174.021.
Pełny tekst źródłaLiu, Ilon, Li Jiang, Erik Samuelsson, Sergio Marco Salas, Alexander Beck, Olivia Hack, Daeun Jeong i in. "DIPG-08. THE LANDSCAPE OF TUMOR CELL STATES AND SPATIAL ORGANIZATION IN H3-K27M MUTANT DIFFUSE MIDLINE GLIOMA ACROSS AGE AND LOCATION". Neuro-Oncology 25, Supplement_1 (1.06.2023): i14. http://dx.doi.org/10.1093/neuonc/noad073.055.
Pełny tekst źródłaHübner, Jens-Martin, Torsten Müller, Dimitris N. Papageorgiou, Monika Mauermann, Jeroen Krijgsveld, Robert B. Russell, David W. Ellison, Stefan M. Pfister, Kristian W. Pajtler i Marcel Kool. "EZHIP/CXorf67 mimics K27M mutated oncohistones and functions as an intrinsic inhibitor of PRC2 function in aggressive posterior fossa ependymoma". Neuro-Oncology 21, nr 7 (29.04.2019): 878–89. http://dx.doi.org/10.1093/neuonc/noz058.
Pełny tekst źródłaLiapodimitri, Athanasia, Kayleigh Lunsford, Ashley R. Tetens, Jordyn Craig-Schwartz, Farhad Vesuna, Venu Raman i Michael A. Koldobskiy. "DIPG-64. UNRAVELING H3K27M INTERACTIONS IN DIFFUSE MIDLINE GLIOMA". Neuro-Oncology 26, Supplement_4 (18.06.2024): 0. http://dx.doi.org/10.1093/neuonc/noae064.117.
Pełny tekst źródłaAndrade, Augusto Faria, Danai Topouza, Michael McNicholas, Eduardo G. Gonzalez Santiago, Antonella De Cola, Arne Gehlhaar, Selin Jessa i in. "TMIC-04. IMMUNE PROFILING OF PEDIATRIC ONCOHISTONE GLIOMAS REVEALS DIVERSE MYELOID POPULATIONS AND TUMOR-PROMOTING BEHAVIORS". Neuro-Oncology 25, Supplement_5 (1.11.2023): v278. http://dx.doi.org/10.1093/neuonc/noad179.1070.
Pełny tekst źródłaBudd, Kaitlin, Chang-Hyuk Kwon, Lawryn H. Kasper, Christopher Roberts, Jordan Roach, Jennifer Ocasio-Adorno, Jon D. Larson i Suzanne J. Baker. "Abstract IA007: Transforming chromatin: Oncohistone mutations in pediatric high-grade glioma". Cancer Research 82, nr 23_Supplement_2 (1.12.2022): IA007. http://dx.doi.org/10.1158/1538-7445.cancepi22-ia007.
Pełny tekst źródłaKida, Jun-ichiro, Takayuki Tsujioka, Shin-ichiro Suemori, Shuichiro Okamoto, Kanae Sakakibara, Takahiro Yamauchi, Akira Kitanaka, Yumi Tohyama i Kaoru Tohyama. "Malignant Progression of an MDS-Derived Cell Line Serves As an in Vitro Model for the Leukemic Evolution of MDS". Blood 132, Supplement 1 (29.11.2018): 5501. http://dx.doi.org/10.1182/blood-2018-99-110583.
Pełny tekst źródłaHohm, Annika, Michael Karremann, Gerrit H. Gielen, Torsten Pietsch, Monika Warmuth-Metz, Lindsey A. Vandergrift, Brigitte Bison i in. "Magnetic Resonance Imaging Characteristics of Molecular Subgroups in Pediatric H3 K27M Mutant Diffuse Midline Glioma". Clinical Neuroradiology 32, nr 1 (17.12.2021): 249–58. http://dx.doi.org/10.1007/s00062-021-01120-3.
Pełny tekst źródłaZhang, Peng, Tiantian Han, Yi Lu, Weijie Sun, Wanglong Deng, Guanghua Lu, Didi Guo, Xiaomin Li i Fanfeng Bu. "Molecular characteristics of H3 K27M mutation gliomas in Chinese adults." Journal of Clinical Oncology 39, nr 15_suppl (20.05.2021): e14018-e14018. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.e14018.
Pełny tekst źródłaShema, Efrat. "Abstract PR006: Single-molecule and single-cell epigenetics: Decoding the epigenome for cancer research and diagnostics". Cancer Research 82, nr 23_Supplement_2 (1.12.2022): PR006. http://dx.doi.org/10.1158/1538-7445.cancepi22-pr006.
Pełny tekst źródłaMorita, Shuhei, Masayuki Nitta, Yoshihiro Muragaki, Takashi Komori, Kenta Masui, Takashi Maruyama, Koichi Ichimura i in. "Brainstem pilocytic astrocytoma with H3 K27M mutation: case report". Journal of Neurosurgery 129, nr 3 (wrzesień 2018): 593–97. http://dx.doi.org/10.3171/2017.4.jns162443.
Pełny tekst źródłaOdia, Yazmin, Ashley Love Sumrall, Timothy Francis Cloughesy, Phioanh Leia Leia Nghiemphu, Matthew David Hall, Doured Daghistani, Minesh P. Mehta i in. "Single agent activity of ONC201 in non-midline H3 K27M-mutant diffuse gliomas." Journal of Clinical Oncology 39, nr 15_suppl (20.05.2021): e14037-e14037. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.e14037.
Pełny tekst źródłaOdia, Yazmin, Ashley Sumrall, Timothy Cloughesy, Phioanh Nghiemphu, Matthew Hall, Doured Daghistani, Minesh Mehta i in. "CTNI-27. SINGLE AGENT ACTIVITY OF ONC201 IN NON-MIDLINE H3 K27M-MUTANT DIFFUSE GLIOMAS". Neuro-Oncology 23, Supplement_6 (2.11.2021): vi65. http://dx.doi.org/10.1093/neuonc/noab196.252.
Pełny tekst źródłaGardner, Sharon L., Carl Johannes Koschmann, Rohinton Tarapore, Jeffrey C. Allen, Wafik Tharwat Zaky, Yazmin Odia, Matthew Hall i in. "ONC201 in previously irradiated pediatric H3 K27M-mutant glioma or newly diagnosed DIPG." Journal of Clinical Oncology 38, nr 15_suppl (20.05.2020): 3619. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.3619.
Pełny tekst źródłaKawakibi, Abed Rahman, Rohinton S. Tarapore, Sharon Gardner, Andrew Chi, Sylvia Kurz, Patrick Y. Wen, Isabel Arrillaga-Romany i in. "HGG-18. CLINICAL EFFICACY OF ONC201 IN THALAMIC H3 K27M-MUTANT GLIOMA". Neuro-Oncology 22, Supplement_3 (1.12.2020): iii347. http://dx.doi.org/10.1093/neuonc/noaa222.305.
Pełny tekst źródłaKawakibi, Abed Rahman, Rohinton Tarapore, Sharon L. Gardner, Sylvia Christine Kurz, Patrick Y. Wen, Isabel Arrillaga-Romany, Tracy Batchelor i in. "Clinical efficacy of ONC201 in thalamic H3 K27M-mutant glioma." Journal of Clinical Oncology 38, nr 15_suppl (20.05.2020): 3617. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.3617.
Pełny tekst źródłaHall, Matthew D., Yazmin Odia, Joshua E. Allen, Rohinton Tarapore, Ziad Khatib, Toba N. Niazi, Doured Daghistani i in. "First clinical experience with DRD2/3 antagonist ONC201 in H3 K27M–mutant pediatric diffuse intrinsic pontine glioma: a case report". Journal of Neurosurgery: Pediatrics 23, nr 6 (czerwiec 2019): 719–25. http://dx.doi.org/10.3171/2019.2.peds18480.
Pełny tekst źródłaSchulte, Jessica, Robin Buerki, Sarah Lapointe, Annette Molinaro, Yalan Zhang, Javier Villanueva-Meyer, Arie Perry i in. "PATH-30. CLINICAL AND GENETIC CHARACTERISTICS OF HISTONE H3 K27M-MUTANT DIFFUSE MIDLINE GLIOMAS IN ADULTS". Neuro-Oncology 22, Supplement_2 (listopad 2020): ii170—ii171. http://dx.doi.org/10.1093/neuonc/noaa215.711.
Pełny tekst źródłaLiu, Ilon, Li Jiang, Erik R. Samuelsson, Sergio Marco Salas, Alexander Beck, Olivia A. Hack, Daeun Jeong i in. "The landscape of tumor cell states and spatial organization in H3-K27M mutant diffuse midline glioma across age and location". Nature Genetics 54, nr 12 (grudzień 2022): 1881–94. http://dx.doi.org/10.1038/s41588-022-01236-3.
Pełny tekst źródłaRahman Kawakibi, Abed, Sharon Gardner, Andrew Chi, Sylvia Kurz, Patrick Wen, Isabel Arrillaga-Romany, Tracy Batchelor i in. "PDCT-12. CLINICAL EFFICACY OF ONC201 IN THALAMIC H3 K27M-MUTANT GLIOMA". Neuro-Oncology 21, Supplement_6 (listopad 2019): vi186. http://dx.doi.org/10.1093/neuonc/noz175.773.
Pełny tekst źródłaQiu, Tianming, Apisara Chanchotisatien, Zhiyong Qin, Jinsong Wu, Zunguo Du, Xialing Zhang, Fangyuan Gong, Zhenwei Yao i Shuguang Chu. "Imaging characteristics of adult H3 K27M-mutant gliomas". Journal of Neurosurgery 133, nr 6 (grudzień 2020): 1662–70. http://dx.doi.org/10.3171/2019.9.jns191920.
Pełny tekst źródłaChen, Xueling, Ling Zhong, Jianwen Lin i Jian Yu. "A rare case of adult diffuse midline glioma with H3 K27M mutant in the prepontine cistern". Journal of International Medical Research 49, nr 1 (styczeń 2021): 030006052098126. http://dx.doi.org/10.1177/0300060520981266.
Pełny tekst źródłaArrillaga-Romany, Isabel, Andrew Lassman, Susan McGovern, Sabine Mueller, L. Burt Nabors, Martin van den Bent, Michael Vogelbaum i in. "RTID-01. ONC108: A RANDOMIZED PHASE 3 STUDY OF ONC201 IN PATIENTS WITH NEWLY DIAGNOSED H3 K27M-MUTANT DIFFUSE GLIOMA". Neuro-Oncology 24, Supplement_7 (1.11.2022): vii249. http://dx.doi.org/10.1093/neuonc/noac209.961.
Pełny tekst źródłaArrillaga-Romany, I., A. Lassman, S. L. McGovern, S. Mueller, L. B. Nabors, M. van den Bent, M. Vogelbaum i in. "P11.46.A ACTION: A RANDOMIZED PHASE 3 STUDY OF DORDAVIPRONE (ONC201) IN PATIENTS WITH NEWLY DIAGNOSED H3 K27M-MUTANT DIFFUSE GLIOMA". Neuro-Oncology 25, Supplement_2 (1.09.2023): ii84. http://dx.doi.org/10.1093/neuonc/noad137.280.
Pełny tekst źródłaArrillaga-Romany, Isabel, Andrew Lassman, Susan McGovern, Sabine Mueller, Louis Burt Nabors, Martin van den Bent, Michael Vogelbaum i in. "TIPS-08 ACTION: A RANDOMIZED PHASE 3 STUDY OF DORDAVIPRONE (ONC201) IN PATIENTS WITH NEWLY DIAGNOSED H3 K27M-MUTANT DIFFUSE GLIOMA". Neuro-Oncology Advances 5, Supplement_3 (1.08.2023): iii35—iii36. http://dx.doi.org/10.1093/noajnl/vdad070.139.
Pełny tekst źródłaDeMasters, B. K., Samuel Guzman i David Ormond. "PATH-18. MORE UNUSUAL FEATURES IN H3 K27M-MUTANT GLIOMAS". Neuro-Oncology 25, Supplement_5 (1.11.2023): v171. http://dx.doi.org/10.1093/neuonc/noad179.0648.
Pełny tekst źródłaArrillaga-Romany, Isabel, Andrew Lassman, Susan L. McGovern, Sabine Mueller, Louis B. Nabors, Martin van den Bent, Michael Vogelbaum i in. "Abstract CT060: ACTION: A randomized phase 3 study of dordaviprone (ONC201) in patients with newly diagnosed H3 K27M-mutant diffuse glioma". Cancer Research 83, nr 8_Supplement (14.04.2023): CT060. http://dx.doi.org/10.1158/1538-7445.am2023-ct060.
Pełny tekst źródłaGardner, Sharon, Rohinton Tarapore, Jeffrey Allen, Wafik Zaky, Yazmin Odia, Matthew Hall, Doured Daghistani i in. "DIPG-52. PHASE I CLINICAL TRIAL OF ONC201 IN PEDIATRIC H3 K27M-MUTANT GLIOMA OR NEWLY DIAGNOSED DIPG". Neuro-Oncology 22, Supplement_3 (1.12.2020): iii297. http://dx.doi.org/10.1093/neuonc/noaa222.097.
Pełny tekst źródłaGardner, Sharon L., Jeffrey C. Allen, Wafik Tharwat Zaky, Yazmin Odia, Doured Daghistani, Ziad Khatib, Carl Johannes Koschmann i in. "ONC201 in previously-irradiated pediatric H3 K27M-mutant glioma." Journal of Clinical Oncology 37, nr 15_suppl (20.05.2019): 10046. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.10046.
Pełny tekst źródłaOdia, Yazmin, Carl Johannes Koschmann, Rohinton Tarapore, Jeffrey Allen, Wafik Tharwat Zaky, Matthew David Hall, Doured Daghistani i in. "Window-of-opportunity study of ONC201 in pediatric patients with diffuse intrinsic pontine glioma (DIPG) and thalamic glioma." Journal of Clinical Oncology 40, nr 16_suppl (1.06.2022): TPS2082. http://dx.doi.org/10.1200/jco.2022.40.16_suppl.tps2082.
Pełny tekst źródłaLiu, Ilon, Jiang Li, Erik Samuelsson, Sergio Marco Salas, Alexander Beck, Olivia Hack, Daeun Jeong i in. "EPCO-21. THE SPATIAL ORGANIZATION OF H3-K27M MUTANT DIFFUSE MIDLINE GLIOMA". Neuro-Oncology 24, Supplement_7 (1.11.2022): vii120. http://dx.doi.org/10.1093/neuonc/noac209.456.
Pełny tekst źródłaJia, Deze, Yi Lu, Xiaomin Li, Tiantian Han, Wanglong Deng, Fanfeng Bu i Guanghua Lu. "Comparison of next-generation sequencing and FISH/IHC for molecular classification in glioma." Journal of Clinical Oncology 39, nr 15_suppl (20.05.2021): e14021-e14021. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.e14021.
Pełny tekst źródłaOdia, Yazmin, Carl Koschmann, Rohinton Tarapore, Jeffrey Allen, Matthew Hall, Doured Daghistani, Ziad Khatib i in. "SYST-07 WINDOW-OF-OPPORTUNITY STUDY OF ONC201 IN PEDIATRIC PATIENTS WITH DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG) AND THALAMIC GLIOMA". Neuro-Oncology Advances 4, Supplement_1 (1.08.2022): i22. http://dx.doi.org/10.1093/noajnl/vdac078.086.
Pełny tekst źródłaArrillaga-Romany, Isabel, Sylvia Kurz, Ashley Sumrall, Nicholas Butowski, Rebecca Harrison, John DeGroot, Andrew Chi i in. "ACTR-34. SINGLE AGENT ONC201 IN PREVIOUSLY-TREATED, PROGRESSIVE ADULT H3 K27M-MUTANT GLIOMA". Neuro-Oncology 21, Supplement_6 (listopad 2019): vi20—vi21. http://dx.doi.org/10.1093/neuonc/noz175.077.
Pełny tekst źródłaKurz, Sylvia Christine, Rohinton Tarapore, Yazmin Odia, Nicholas A. Butowski, Carl Johannes Koschmann, Dolly Aguilera, Tobey J. MacDonald i in. "Clinical experience of ONC201 in patients with recurrent H3 K27M-mutant spinal cord glioma." Journal of Clinical Oncology 38, nr 15_suppl (20.05.2020): 2563. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.2563.
Pełny tekst źródłaArrillaga-Romany, Isabel, Sylvia Christine Kurz, Rohinton Tarapore, Ashley Sumrall, Nicholas A. Butowski, Rebecca A. Harrison, John Frederick De Groot i in. "Single-agent ONC201 in recurrent H3 K27M-mutant diffuse midline glioma." Journal of Clinical Oncology 38, nr 15_suppl (20.05.2020): 3615. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.3615.
Pełny tekst źródłaGessi, Marco, David Capper, Felix Sahm, Kristin Huang, Andreas von Deimling, Stephan Tippelt, Gudrun Fleischhack i in. "Evidence of H3 K27M mutations in posterior fossa ependymomas". Acta Neuropathologica 132, nr 4 (18.08.2016): 635–37. http://dx.doi.org/10.1007/s00401-016-1608-3.
Pełny tekst źródłaSchniederjan, Matthew J., Cahil Potnis, Varshini Vasudevaraja, Catherine D. Moser, Bethany Watson, Matija Snuderl, Tobey MacDonald i Beverly B. Rogers. "DNA Methylation Profiles Are Stable in H3 K27M-Mutant Diffuse Midline Glioma Neurosphere Cell Lines". Children 11, nr 4 (20.04.2024): 492. http://dx.doi.org/10.3390/children11040492.
Pełny tekst źródłaDiaz, Maria, Carlos Eduardo Silva Correia, Andrew Lin, Alexandra Miller i Elena Pentsova. "PATH-04. LEPTOMENINGEAL DISEASE IN PATIENTS WITH HISTONE-MUTANT GLIOMAS". Neuro-Oncology 23, Supplement_6 (2.11.2021): vi115. http://dx.doi.org/10.1093/neuonc/noab196.457.
Pełny tekst źródłaPorter, William, Joshua Sulman, Katie Foot, Ruman Rahman, Richard Grundy, Robert Layfield i Farhana Haque. "HGG-47. Comparative analysis of the Histone H3 mutant protein interactome landscape in paediatric high-grade gliomas". Neuro-Oncology 24, Supplement_1 (1.06.2022): i71—i72. http://dx.doi.org/10.1093/neuonc/noac079.262.
Pełny tekst źródłaArrillaga-Romany, Isabel, Sylvia Kurz, Rohinton S. Tarapore, Ashley Sumrall, Nicholas Butowski, Rebecca Harrison, John de Groot i in. "CTNI-37. EFFICACY OF ONC201 IN PATIENTS WITH ONC201 FOR RECURRENT H3 K27M-MUTANT DIFFUSE MIDLINE GLIOMA". Neuro-Oncology 22, Supplement_2 (listopad 2020): ii50—ii51. http://dx.doi.org/10.1093/neuonc/noaa215.204.
Pełny tekst źródłaHaque, Farhana. "Comparative Analysis of the Histone H3 Mutant Protein Interactome Landscape in Paediatric High-Grade Gliomas". Neuro-Oncology 24, Supplement_4 (1.10.2022): iv4. http://dx.doi.org/10.1093/neuonc/noac200.016.
Pełny tekst źródłaBalakrishnan, Samantha, Ivan Carabenciov, Michael Ruff, Joon Uhm i Sani Kizilbash. "RARE-37. TREATMENT OF H3K27M MUTANT GLIOMAS WITH PANOBINOSTAT". Neuro-Oncology 21, Supplement_6 (listopad 2019): vi229. http://dx.doi.org/10.1093/neuonc/noz175.960.
Pełny tekst źródłaSumrall, Ashley Love, Joanne Xiu, Jennifer M. Eschbacher, Sandeep Mittal, Zoran Gatalica, Manjari K. Pandey, Surasak Phuphanich, Wolfgang Michael Korn, Gregory N. Fuller i Amy B. Heimberger. "Mutations of H3.3 and H3.1 in a large cohort of glioma tumors." Journal of Clinical Oncology 37, nr 15_suppl (20.05.2019): e13540-e13540. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.e13540.
Pełny tekst źródłaArrillaga, Isabel, Sylvia Kurz, Ashley Sumrall, Nicholas A. Butowski, Rebecca A. Harrison, John Frederick De Groot, Nicole A. Shonka i in. "Single agent ONC201 in adult recurrent H3 K27M-mutant glioma." Journal of Clinical Oncology 37, nr 15_suppl (20.05.2019): 3005. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.3005.
Pełny tekst źródłaAzadi, Amir, Ekokobe Fonkem i Tejas Ranade. "EPID-12. TREATMENT OUTCOMES OF MIDLINE GLIOMAS WITH H3K27 M: OUR BARROW NEUROLOGICAL INSTITUTE EXPERIENCE". Neuro-Oncology 22, Supplement_2 (listopad 2020): ii81. http://dx.doi.org/10.1093/neuonc/noaa215.330.
Pełny tekst źródłaGardner, Sharon, Carl Koschmann, Rohinton Tarapore, Jeffrey Allen, Wafik Zaky, Yazmin Odia, Matthew Hall i in. "CTNI-36. SAFETY OF ONC201 ADMINISTERED TWO CONSECUTIVE DAYS PER WEEK IN PEDIATRIC H3 K27M-MUTANT GLIOMA PATIENTS". Neuro-Oncology 23, Supplement_6 (2.11.2021): vi67. http://dx.doi.org/10.1093/neuonc/noab196.261.
Pełny tekst źródłaDamodharan, Sudarshawn, Montserrat Lara-Velazquez, Brooke Carmen Williamsen, Jeffrey Helgager i Mahua Dey. "Diffuse Intrinsic Pontine Glioma: Molecular Landscape, Evolving Treatment Strategies and Emerging Clinical Trials". Journal of Personalized Medicine 12, nr 5 (20.05.2022): 840. http://dx.doi.org/10.3390/jpm12050840.
Pełny tekst źródłaGrebstad Tune, Benedicte, Heena Sareen, Branka Powter, Smadar Kahana-Edwin, Adam Cooper, Eng-Siew Koh, Cheok S. Lee i in. "From Pediatric to Adult Brain Cancer: Exploring Histone H3 Mutations in Australian Brain Cancer Patients". Biomedicines 11, nr 11 (27.10.2023): 2907. http://dx.doi.org/10.3390/biomedicines11112907.
Pełny tekst źródła